BioCentury
ARTICLE | Company News

KeyNeurotek, Max Planck Society deal

February 19, 2007 8:00 AM UTC

KeyNeurotek received exclusive rights to Max Planck’s method for identifying drug candidates that have an effect on FK506 binding proteins. The company also amended its collaboration with the society...